Acute Myeloid Leukaemia (AML) with Retinoic acid receptor-gamma (RARG) fusions have similarities to Acute Promyelocytic Leukemia (APL) but are not responsive to standard APL treatments.

Pembrolizumab is under clinical development by Merck and currently in Phase I for Kaposi Sarcoma. According to GlobalData ... or as a single agent after one or more prior lines of systemic therapy for ...

About 9,560 new cases will be diagnosed with CML (5,610 in men and 3,950 in women) About 1,290 people will die of CML (740 men and 550 women) About 15% of all new cases of leukemia are chronic myeloid ...

Information on treatment success rates for AML in adults can be found in Treatment Response Rates for Acute Myeloid Leukemia. Our team is made up of doctors and oncology certified nurses with deep ...

Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases. Additionally, the Company is ...

Myeloproliferative neoplasms are blood cancers that affect myeloid stem cells. Treatment can involve targeted medications or careful monitoring. Myeloproliferative disorders are a group of cancers ...

Thus, in this review, we summarize our current understanding of the interaction between nociceptors and, specifically, the myeloid cells of the innate immune system, while pointing out some of the ...

1Department of Medicine, Sarcoma Medical Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York. 2Department of Medicine, Weill Cornell Medical College, New York, New York.